切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2018, Vol. 07 ›› Issue (01) : 36 -41. doi: 10.3877/cma.j.issn.2095-3224.2018.01.008

所属专题: 文献

论著

Chymase蛋白在结直肠癌组织中的表达及意义
陶金华1, 崔健2, 张帆3, 陈佳楠1, 王贵玉4, 刘正1,(), 王锡山1   
  1. 1. 100021 北京,国家癌症中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科
    2. 100730 北京医院胃肠外科、国家老年医学中心
    3. 065099 廊坊,中国石油天然气集团公司中心医院普外科
    4. 150086 哈尔滨医科大学附属第二医院结直肠肿瘤外科、哈尔滨医科大学大肠癌研究所
  • 收稿日期:2017-06-19 出版日期:2018-02-25
  • 通信作者: 刘正
  • 基金资助:
    国家自然科学基金应急管理项目(No.81641181); 国家重点研发计划精准医学研究专项(No.2016YFC0905300); 黑龙江省自然科学基金青年项目(No.QC2013C086); 中国医学科学院医学与健康科技创新工程项目(No.2016-I2M-1-001); 中国医学科学院基本科研业务费项目(No.2016ZX320012)

The expression and clinical significance of Chymase protein in colorectal cancer tissue

Jinhua Tao1, Jian Cui2, Fan Zhang3, Jianan Chen1, Guiyu Wang4, Zheng Liu1,(), Xishan Wang1   

  1. 1. Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    2. Department of Gastrointestinal Surgery, Beijing Hospital, National Center of Gerontology, Beijing 100730, China
    3. Department of General Surgery, The Central Hospital of China National Petroleum Corporation, Langfang 065099, China
    4. Department of Colorectal Cancer Surgery, The Second Affiliated Hospital, Harbin Medical University, Colorectal Cancer Institute of Harbin Medical University, Harbin 150086, China
  • Received:2017-06-19 Published:2018-02-25
  • Corresponding author: Zheng Liu
  • About author:
    Corresponding author: Liu Zheng, Email:
引用本文:

陶金华, 崔健, 张帆, 陈佳楠, 王贵玉, 刘正, 王锡山. Chymase蛋白在结直肠癌组织中的表达及意义[J/OL]. 中华结直肠疾病电子杂志, 2018, 07(01): 36-41.

Jinhua Tao, Jian Cui, Fan Zhang, Jianan Chen, Guiyu Wang, Zheng Liu, Xishan Wang. The expression and clinical significance of Chymase protein in colorectal cancer tissue[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(01): 36-41.

目的

探讨Chymase蛋白在结直肠癌组织中的表达及临床意义。

方法

选取2010年9月至2012年9月于中国医学科学院肿瘤医院结直肠外科和哈尔滨医科大学附属第二医院结直肠肿瘤外科接受结直肠癌根治术的135例结直肠癌患者,通过免疫组化的方法检测Chymase蛋白在结直肠癌组织中的表达,分析Chymase蛋白与临床病理资料及预后的关系。

结果

Chymase蛋白在结直肠癌组织中的表达低于癌旁组织,表达差异具有统计学意义(Χ2=4.305,P=0.038),结直肠癌组织中,有远处转移患者Chymase蛋白表达降低(P=0.002),Chymase蛋白的表达与N分期有关,分期越晚,Chymase蛋白的表达越低(Χ2=54.81,P<0.001),在Ⅲ+Ⅳ期患者Chymase蛋白表达降低(Χ2=50.84,P<0.001),生存分析结果提示Chymase蛋白低表达患者预后不佳(Χ2=10.501,P=0.001)。

结论

Chymase蛋白可能成为结直肠癌患者预后的分子靶标。

Objective

To investigate the expression and clinical significance of chymase protein in colorectal cancer tissue.

Methods

135 colorectal cancer patients who underwent radical resection were collected at the Cancer Hospital Chinese Academy of Medical Sciences and the Second Affiliated Hospital of Harbin Medical University between September 2010 and September 2012. The expression of Chymase protein in colorectal cancer tissue was detected by immunohistochemistry, and the relationship between Chymase protein and clinicopathological data and prognosis was analyzed.

Results

The expression of chymase protein in colorectal cancer tissue was lower than that of the adjacent tissues, the difference was of statistically significance (Χ2=4.305, P=0.038). In colorectal cancer tissue, the expression of chymase protein was decreased in distant metastatic patients (P=0.002), the expression of chymase protein was decreased in late N staging (Χ2=54.81, P<0.001), the expression of chymase protein was decreased in Ⅲ+ Ⅳ patients (Χ2=50.84, P<0.001), survival analysis indicated that patients with low expression of chymase protein had poor prognosis (X2=10.501, P=0.001).

Conclusion

Chymase protein may be a molecular target for prognosis of colorectal cancer.

表1 Chymase蛋白在结直肠癌组织及癌旁组织中的表达
图1 Chymase蛋白在结直肠癌及癌旁组织中的表达,1A在结直肠癌组织中低表达;1B在癌旁组织中高表达
表2 Chymase的表达及与临床病理资料之间的关系
表3 135例结直肠癌患者总生存的危险因素单因素分析
表4 135例结直肠癌患者总生存的危险因素多因素分析
图2 Chymase蛋白的高低表达对135例结直肠癌患者总生存的影响
[1]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[2]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]
Shaw JA, Graham TA, Stebbing J. Genomic instability in pre-neoplastic colonic lesions [J]. Oncogene, 2013, 32(46): 5331-5332.
[4]
Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy [J]. Nat Rev Cancer, 2010, 10(8): 575-585.
[5]
O′Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer [J]. N Engl J Med, 2013, 368(2): 161-170.
[6]
Shenoy AK, Fisher RC, Butterworth EA, et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors [J]. Cancer Res, 2012, 72(19): 5091-5100.
[7]
Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets [J]. Immunity, 2012, 37(1): 25-33.
[8]
Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut [J]. Biochim Biophys Acta, 2012, 1822(1): 85-92.
[9]
He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases [J]. Curr Pharm Des, 2013, 19(6): 1114-1125.
[10]
Heuston S, Hyland NP. Chymase inhibition as a pharmacological target: a role in inflammatory and functional gastrointestinal disorders? [J]. Br J Pharmacol, 2012, 167(4): 732-740.
[11]
Groschwitz KR, Wu D, Osterfeld H, et al. Chymase mediated intestinal epithelial permeability is regulated by protease activating receptor (PAR)-2/ matrix metalloproteinase (MMP)-2-dependent mechanism [J]. Am J Physiol Gastrointest Liver Physiol, 2013 Jan 10 [Epub ahead of print].
[12]
Cho EY, Choi SC, Lee SH, et al. Nafamostat mesilate attenuates colonic inflammation and mast cell infiltration in the experimental colitis [J]. Int Immunopharmacol, 2011, 11 (4): 412-417.
[13]
Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study [J]. N Eng J Med, 1990, 323: 1228-1233.
[14]
Choi CR, Al Bakir I, Ding NJ, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study [J]. Gut, 2017, pii: gutjnl-2017-314190.
[15]
Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study [J]. JAMA Oncol, 2017 Aug 10: e172319. [Epub ahead of print].
[16]
Wimberly AL, Forsyth CB, Khan MW, et al. Ethanol-induced mast cell-mediated inflammation leads to increased susceptibility of intestinal tumorigenesis in the APC Δ468 min mouse model of colon cancer [J]. Alcohol Clin Exp Res, 2013, 37(1): 199-208.
[17]
Schwitalla S, Ziegler PK, Horst D, et al. Loss of p53 in Enterocytes Generates an Inflammatory Microenvironment Enabling Invasion and Lymph Node Metastasis of Carcinogen-Induced Colorectal Tumors [J]. Cancer Cell, 2013, 23(1): 93-106.
[18]
Acikalin MF, Oner U, Topçu I, et al. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas [J]. Dig Liver Dis, 2005, 37(3): 162-169.
[19]
Sinnamon MJ, Carter KJ, Sims LP, et al. A protective role of mast cells in intestinal tumorigenesis [J]. Carcinogenesis, 2008, 29(4): 880-886.
[20]
Mehdawi L, Osman J, Topi G, et al. High tumor mast cell density is associated with longer survival of colon cancer patients [J]. Acta Oncol, 2016, 55(12): 1434-1442.
[21]
Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue [J]. J Pathol, 1999, 189(4): 487-495.
[22]
Tan SY, Fan Y, Luo HS, et al. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer [J]. World J Gastroenterol, 2005, 11(8): 1210-1214.
[23]
Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer [J]. J Gastroenterol Hepatol, 2009, 24(7): 1265-1275.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[10] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[11] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[12] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[13] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要